This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
After initial data read-out in Part 1, study may possibly be expanded and continued in Part 2 for use as a potential registration study
Patient recruitment expected to start soon
COPENHAGEN, Denmark, Sept. 10, 2013 (GLOBE NEWSWIRE) --
Genmab A/S (OMX:GEN)
announced today that its partner, Janssen Biotech, Inc. ("Janssen") will start a new Phase II study of daratumumab in multiple myeloma. The Phase II study is designed in 2 parts in multiple myeloma patients who have received at least three different lines of therapy including both a proteasome inhibitor and an immunomodulatory agent (IMiD) or who are double refractory to a proteasome inhibitor and an IMiD. This is the same indication for which daratumumab was granted Breakthrough Therapy Designation from the FDA in May 2013.
"We continue to be excited by the prospects for daratumumab, which has the potential to offer a significant therapeutic alternative for multiple myeloma patients who desperately seek new treatment options," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. "We look forward to the initiation of this trial with daratumumab in multiple myeloma patients, and we believe this study has the potential to be used for registration in the United States."
About the Study This two-part study will enroll up to a maximum of 110 patients who have received at least three prior lines of therapy, including both a proteasome inhibitor and an IMiD or who are double refractory to a proteasome inhibitor and an IMiD. Examples of proteasome inhibitors are bortezomib or carfilzomib and examples of IMiD agents are pomalidomide or lenalidomide. Part 1 will define an optimal daratumumab regimen going forward, while part 2 is an expansion based on the optimal regimen determined in Part 1. The primary objective of the study is to define the optimal dose and dosing schedule, to determine the efficacy of two treatment regimens of daratumumab as measured by overall response rate, and to further characterize the safety of daratumumab as a single agent.
About daratumumab Daratumumab is a human CD38 monoclonal antibody with broad-spectrum killing activity. Daratumumab is in clinical development for multiple myeloma (MM). Daratumumab targets the CD38 molecule which is highly expressed on the surface of multiple myeloma cells. Daratumumab could also have potential in other cancers on which CD38 is expressed, including diffuse large B-cell lymphoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, plasma cell leukemia, acute myeloid leukemia, follicular lymphoma and mantle cell lymphoma. Daratumumab has been granted Breakthrough Therapy Designation from the US FDA. In August 2012, Genmab granted Janssen Biotech, Inc. an exclusive worldwide license to develop and commercialize daratumumab.
About Genmab A/S Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. Founded in 1999, the company's first marketed antibody, ofatumumab (Arzerra
(r)), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development. Genmab's validated and next generation antibody technologies are expected to provide a steady stream of future product candidates. Partnering of innovative product candidates and technologies is a key focus of Genmab's strategy and the company has alliances with top tier pharmaceutical and biotechnology companies. For more information visit
Contact: Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications T: +45 33 44 77 20; M: +45 25 12 62 60; E:
email@example.comThis Company Announcement contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law. Genmab A/S and its subsidiaries own the following trademarks: Genmab
(R); the Y-shaped Genmab logo
(R); Genmab in combination with the Y-shaped Genmab logo
TM; the DuoBody(TM) logo; HuMax
TM and UniBody
(R) is a registered trademark of GlaxoSmithKline.
Company Announcement no. 39 CVR no. 2102 3884